Proteomic profiling of peripheral blood neutrophils identifies two inflammatory phenotypes in stable COPD patients

Table 2 Clinical data of COPD group 1 and COPD group 2

Clinical parameters	COPD group 1 (N = 17)	COPD group 2 (N = 24)	Statistics
Age, yrs	59 ± 6	61 ± 9	0.367
FEV1, L	1.89 ± 1.27	1. 40 ± 0.69	0.167
FEV1, % predicted	56 ± 30	46 ± 22	0.259
FEV1/FVC ratio	44 ± 15	39 ± 12	0.214
Pack years	46 ± 18	38 ± 14	0.160
DLCO	56 ± 20	60 ± 21	0.531
P15, HU	−946 ± 23	−953 ± 22	0.392
6MWD, m	472 ± 106	476 ± 131	0.904
Pack years	46 ± 18	38 ± 14	0.160
MRC dyspnoe scale	2.2 ± 1.1	2.6 ± 1.4	0.414
CCQ total score	2.1 ± 1.2	1.9 ± 1.1	0.696
SGRQ total score	44 ± 19	44 ± 17	0.899
BODE index	3.1 ± 2.7	3.4 ± 2.5	0.718
hsCRP	4.3 ± 5.4	4.9 ± 7.8	0.779
Leukocyte count	7.7 ± 1.6	7.7 ± 2.0	0.931

FEV1 Forced Expiratory Volume 1, FVC Forced Vital Capacity, DLCO Diffusion capacity of the lung for carbon monoxide, P15 15th percentile, HU hounsfield unit, 6MWD 6 min walking distance, CCQ Clinical COPD Questionnaire, SGRQ St. George’s Respiratory Questionnaire

ISSN: 1465-993X